Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
rutlandherald|2/18/2026|depression
Share this article:
Share this article:
Related Articles
More stories about depression
Pristiq (desvenlafaxine)
December 31, 2025
What is the relationship between depression and hepatitis C?
December 30, 2025
Celexa (citalopram)
December 29, 2025
Infertility and depression: Symptoms and coping
December 28, 2025